The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
November 9th 2024
Reasons for supporting the lowering of the age-based pneumococcal vaccine recommendation included the likelihood it would increase vaccination rates in multiple age groups and demographics.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Role of the Pharmacist in Influenza Prevention for At-Risk Adults: Strategies to Enhance Immunization
1.5 Credits / Infectious Disease
View More
The Essential Role of Pharmacists in Improving Influenza Vaccination Coverage: Strategies to Increase Vaccine ...
1.0 Credit / Immunization, Infectious Disease
View More
The Role of Pharmacists in Pneumococcal Prevention: Strategies to Improve Vaccine Uptake
1.0 Credit / Immunization, Infectious Disease, Pulmonology
View More
Investigational Vaccine Has Non-Inferior Immune Response Compared to PCV20 for Pneumococcal Disease
December 13th 2023Clinical trial results show the immunogenicity, tolerability, and safety of V116 compared to a pneumococcal 20-valent conjugate vaccine for adults who had not previously received a pneumococcal vaccine.
Read More
FDA Approves Pentavalent Vaccine for Most Common Serogroups That Cause Meningococcal Disease
October 20th 2023Penbraya (Pfizer Inc) is the first and only approved pentavalent vaccine that confers protection against the most common meningococcal serogroups—A, B, C, W-135, and Y, in individuals 10 through 25 years of age.
Read More
Nasopharyngeal Swabs Most Sensitive for Pneumococcal Detection in Infants
October 20th 2023Study authors suggest that saliva samples can be a complementary testing method to provide additional information on pneumococcal carriage and serotypes that may be undetected by nasopharyngeal testing.
Read More